STADA Arzneimittel AG / Dividend/Preliminary Results

06.03.2008 

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------

Today, on March 6, 2008, the Executive Board of STADA Arzneimittel AG
decided in an Executive Board meeting to recommend a dividend increase for
the fiscal year 2007 of 15% to EUR 0.71 per STADA share to the Annual
Shareholders' Meeting on June 10, 2008. For the fiscal year 2006, STADA had
paid a dividend of EUR 0.62 per share.

The increased dividend proposal is based on the good preliminary results
for fiscal year 2007.

Accordingly, sales in the reporting period grew by approx. 26% to approx.
EUR 1.57 billion (previous year: EUR 1.25 billion) – and thus for the
twelfth time in a row. Once again, the clear growth of the international
business activities made particularly significant contributions to this.
With a sales increase in 2007 of approx. 30% to approx. EUR 990.7 million
(previous year: EUR 763.2 million) international business’ share of Group
sales now amounts to approx. 63% (previous year: 61%).

In earnings, too, STADA was able to achieve record highs in the history of
the company for the twelfth year in a row.

Net income recorded growth in 2007 of approx. 14% to approx. EUR 105.1
million (previous year: EUR 91.8 million). Total dividend payments of
approx. EUR 41.6 million (previous year: EUR 36.0 million) proposed by the
Executive Board today would thus be equivalent to a distribution ratio of
approx. 40%.

By deducting one-time special effects, adjusted net income in 2007 rose to
approx. EUR 146.8 million (previous year: EUR 102.1 million) and was thus
44% higher than the adjusted net income of the previous year.

The earnings growth achieved in the STADA Group in 2007 can also be seen in
the further preliminary key earnings figures which have all risen to new
record levels, in particular also when the key figures adjusted for
one-time special effects are considered.

Thus, according to the preliminary figures for fiscal year 2007, operating
profit rose by approx. 19% to approx. EUR 215.5 million (previous year: EUR
180.5 million), adjusted operating profit was up by approx. 33% to approx.
EUR 248.8 million (previous year: EUR 186.4 million), earnings before
interest, taxes, depreciation and amortization (EBITDA) increased by
approx. 24% to approx. EUR 289.5 million (previous year: EUR 232.6
million), adjusted earnings before interest, taxes, depreciation and
amortization rose by approx. 35% to approx. EUR 315.7 million (previous
year: EUR 233.0 million), earnings before interest and taxes (EBIT) went up
by approx. 11% to approx. EUR 187.8 million (previous year: EUR 168.7
million), adjusted earnings before interest and taxes rose by approx. 34%
to approx. EUR 249.2 million (previous year: EUR 186.7 million), earnings
before taxes (EBT) increased by approx. 4% to approx. EUR 150.7 million
(previous year: EUR 145.2 million), adjusted earnings before taxes
increased by approx. 30% to approx. EUR 212.1 million (previous year: EUR
163.2 million). Earnings per share rose – taking into consideration that
the average number of shares increased in 2007 by 8% to 58,315,643 shares
(previous year: 53,983,327 shares) due to the exercise of options – by
approx. 6% to approx. EUR 1.80 (previous year: EUR 1.70), adjusted earnings
per share rose to approx. EUR 2.52 (previous year: EUR 1.89). Diluted
earnings per share went up to approx. EUR 1.74 (previous year: EUR 1.62),
adjusted diluted earnings per share increased to approx. EUR 2.42 (previous
year: EUR 1.81).

The adjusted one-time special effects from 2007 for above mentioned key
earnings figures can be divided up as follows:

- A burden in the total amount of approx. EUR 28.1 million before  taxes
(presented below operating profit in accordance with IAS 19)  or approx.
EUR 17.9 million after taxes resulted from the  restructuring measures in
the German STADA generics sales force.  The final burden was thus slightly
below what was expected at the  beginning of the restructuring measures
(see ad hoc release of the  company from September 28, 2007).
- A burden in the amount of approx. EUR 35.3 million before taxes or 
approx. EUR 26.1 million after taxes resulted from unscheduled 
depreciation on intangible assets and financial assets.
- A burden in the amount of approx. EUR 6.2 million before taxes or 
approx. EUR 3.9 million after taxes was based on one-time costs  for
acquisitions planned and/or carried out.
- A relief in the total amount of approx. EUR 5.8 million before  taxes or
approx. EUR 5.0 million after taxes resulted from book  gains from
disposals.
- A relief in the net amount of approx. EUR 2.3 million before taxes  or
approx. EUR 1.4 million after taxes is based on additional  earnings and
costs with one-time or outside of the accounting  period character.

Overall, one-time special effects in fiscal year 2007 amounted to an
expected net burden of approx. EUR 61.5 million before taxes or approx. EUR
41.6 million after taxes; the one-time special effects from fiscal year
2006 had led at that time to a net burden in the total amount of EUR 18.0
million before taxes or EUR 10.3 million after taxes.

At today’s meeting, the Executive Board also decided to confirm the
previous positive outlook in the Annual Report for 2007.

Indeed, in individual national markets significant regulatory
interventions, intensive competition and significant margin pressure will
always occur. With a view to the strategic focus on growth markets and the
proven operative strengths of the Group, however, the Executive Board
expects, from today’s perspective, that STADA will also continue to be able
in the future to achieve a sustained operative growth in a challenging
environment and thereby be able to continue the successful growth course of
the Group in the years to come.

STADA’s final business results for 2007 will be published on March 27,
2008.

Further information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2–18 / 
61118 Bad Vilbel, Germany /
Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / 
E-mail: communications@stada.de
Or visit our website at www.stada.com
DGAP 06.03.2008 
---------------------------------------------------------------------------
Language:     English
Issuer:       STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Deutschland
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf;
              Freiverkehr in Berlin, Hannover, Hamburg, München, Stuttgart
End of News                                     DGAP News-Service
---------------------------------------------------------------------------